Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
Characterization of metabolic and immune dysfunction in B16-F10 metastatic melanomas using high-throughput metabolomics and transcriptomics assays
EF 2012-13
Résumé
Cancerous cells are unique in their ability to uncontrollably divide and form tumours while evading the immune system. This ability is conferred by various cellular mechanisms that promote their ability to produce the energy required to continuously grow as well as suppress the cells' normal immune response. While these metabolic and immune defects allow the tumours to grow, they also make the cancers susceptible in particular ways. For example, cancers have been found to be defective in interferon signalling, a major pathway in the immune response that aids in pathogen and tumour clearance. Defects in this area render cancers vulunerable to oncolytic viruses that are able to specifically target tumour cells due to their inability to mount proper immune responses. I propose to characterize the metabolic and gene transcriptional differences between non-cancerous Melan-A melanocytes, B16-F10 melanoma cells, and B16-F10 melanoma cells infected with Vesicular Stomatits Virus, an oncolytic virus. Using high-throughput techniques that I have previously developed, such as RNA-sequencing (RNAseq) and Liquid Chromatography Mass Spectrometry (LCMS), it is possible to quantitatively assess global transcriptional and metabolic profiles, respectively. Identification of the specific metabolic and immune defense pathways that become aberrant in cancer will inform the development of additional oncolytic virus vaccines and other cancer treatments and drugs that target those defects.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
280284
Name
Lee Keith M
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Canada Graduate Scholarships Master's Awards A
Projecttitle
Characterization of metabolic and immune dysfunction in B16-F10 metastatic melanomas using high-throughput metabolomics and transcriptomics assays
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cancer Immunotherapy; Cancer Vaccines; Oncolytic Viral Therapy
Abstract
Cancerous cells are unique in their ability to uncontrollably divide and form tumours while evading the immune system. This ability is conferred by various cellular mechanisms that promote their ability to produce the energy required to continuously grow as well as suppress the cells' normal immune response. While these metabolic and immune defects allow the tumours to grow, they also make the cancers susceptible in particular ways. For example, cancers have been found to be defective in interferon signalling, a major pathway in the immune response that aids in pathogen and tumour clearance. Defects in this area render cancers vulunerable to oncolytic viruses that are able to specifically target tumour cells due to their inability to mount proper immune responses. I propose to characterize the metabolic and gene transcriptional differences between non-cancerous Melan-A melanocytes, B16-F10 melanoma cells, and B16-F10 melanoma cells infected with Vesicular Stomatits Virus, an oncolytic virus. Using high-throughput techniques that I have previously developed, such as RNA-sequencing (RNAseq) and Liquid Chromatography Mass Spectrometry (LCMS), it is possible to quantitatively assess global transcriptional and metabolic profiles, respectively. Identification of the specific metabolic and immune defense pathways that become aberrant in cancer will inform the development of additional oncolytic virus vaccines and other cancer treatments and drugs that target those defects.
Competitiondate
201302
Approvedterm2
1 yr 0 mth
Pinamesdelim
Lee, Keith M
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~